Tactics to Diffuse Stakeholder Hostility During Product Launch

CHAPEL HILL, N.C., Sep. 28, 2021/PRNewswire/ -- Launching a new breakthrough medicine is often like a double-edged sword for pharma companies. While some drugs go on to achieve blockbuster status owing to factors such as fulfilling an unmet need or first-mover advantage, other drugs face a hostile response from key stakeholder groups in instances where there is stigma or controversy associated with the condition or its treatment.

Considering the millions of dollars at stake during a new product launch, forward-looking pharma companies have developed rapid response teams to map and engage the full range of hostile stakeholder groups. Best Practices, LLC engaged senior launch leadership from pharma companies and conducted extensive secondary research in its new 127-page study "Managing Hostile Stakeholders During the Launch of a Breakthrough New Medicine" to identify effective strategies for managing hostile stakeholders during the launch of a breakthrough new medicine.

Key topics in the report include:

• Developing early warning systems and enabling rapid response to hostile actions issues
• Communication practices that help prevent issues and soften hostile voices
• Mapping and managing hostile groups across the market landscape
• Using science to communicate data to defuse hostility and build the value story
• Working with different hostile stakeholder groups

To learn more about this report on Managing Hostile Stakeholders During Launch, download a complimentary report excerpt here: https://www.best-in-class.com/rw83.htm

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.